Lyra Therapeutics is focused on developing innovative therapies for chronic rhinosinusitis (CRS), a condition affecting millions and often lacking effective treatment options. Their lead product candidate, LYR-210, is a bioabsorbable nasal mesh designed to deliver anti-inflammatory medication directly to the sinonasal passages for up to six months. This long-acting drug therapy aims to provide sustained relief from the debilitating symptoms of CRS, such as nasal congestion and facial pain, by overcoming the limitations of conventional treatment methods. The technology integrates advanced materials engineering with a proven anti-inflammatory medication, allowing for targeted and continuous drug delivery.

The proprietary XTreo™ platform developed by Lyra Therapeutics consists of a biocompatible mesh scaffold, an engineered elastomeric matrix, and a polymer-drug formulation. This combination optimizes drug release while ensuring patient comfort and adaptability to the unique anatomy of the sinonasal passages. The technology is designed to enhance patient compliance by providing a consistent and effective treatment option with a single administration. Lyra Therapeutics has established a robust intellectual property portfolio to protect its innovations, ensuring the continued development and commercialization of its therapies for CRS.

United States

Lyra Therapeutics is a clinical-stage company developing medicines precisely designed to target ear, nose and throat (ENT) diseases. Our goal is to transform the ENT treatment paradigm by providing effective solutions for physicians and new treatment options for their patients.

Lung Diseases

Various

Lyra Therapeutics

Chronic rhinosinusitis

Neurological disorder

Rhinosinusitis

<p class="font_7">LYR-210 is an investigational product candidate designed to be administered in-office, into the sinonasal passages, and to deliver a sustained release therapeutic up to six months at difficult-to-access nasal inflammation sites without the need for patient compliance, as a non-invasive alternative to surgery for patients who have failed medical management.</p>

LYR-210 (anti-inflammatory implantable drug matrix) 

<p class="font_7">LYR-210 is an investigational product candidate that utilizes Lyra’s proprietary XTreo™ platform to enable six months of local anti-inflammatory therapy from a single treatment for chronic rhinosinusitis (CRS). LYR-210 is designed as a non-invasive alternative to sinus surgery for the millions of CRS patients who have failed medical management. In the LANTERN Phase 2 clinical trial, LYR-210 (7500mcg) demonstrated rapid, clinically meaningful and durable symptom improvement in symptom scores over six months.</p>

Lyra Therapeutics

Company Details